NEWS
2024/04/25
alt.ai and GNI Group announce collaboration to use AI in drug discovery and investment fields
Toward a proof of concept aimed at creating an optimal and efficient drug discovery and investment flow using AI
alt Inc. (https://alt.ai/en/), the Japan-based developer and distributor of Personal Artificial Intelligence (P.A.I.®️) and AI clone technology (head office: Minato-ku, Tokyo; CEO: Kazutaka Yonekura), is pleased to announce the beginning of a collaboration with GNI Group Ltd. (head office: Chuo-ku, Tokyo; Director, Representative Executive Officer, President and CEO: Ying Luo, PhD), a leader in drug discovery research and development, on the use of AI in the drug discovery and investment fields.
The primary goal of this collaboration is to combine alt’s AI technologies, including deep learning, generative AI, and large language models, with GNI Group's extensive knowledge, experience, and data related to drug discovery to streamline and optimize the drug discovery process using AI technologies.
By utilizing the latest technologies, including AI-based sequence simulation, we aim to optimize the flow of new drug candidates from discovery to clinical trials to create a more efficient drug discovery process, and by initiating product development to facilitate such optimization, we will contribute to the acceleration of DX in the industry as a whole.
In addition, in establishing the investment business of the GNI Group in the future, we aim to build an optimal process for selecting stocks for investment, including the use of AI screening technology.
Expected Collaboration and Proof of Concept
●AI-based search for candidate compounds for new drug development
・AI enables the rapid discovery of potential new indications for existing drugs.
・Sequence search (using AI simulation) of existing compound libraries will enable the discovery of compounds with improved safety and quality.
・Increases the likelihood of discovering newly developed compounds with new mechanisms of action that are difficult to discover by conventional methods.
●Improving the efficiency of basic research using AI
・Basic research for new drugs is known to be time-consuming and costly. However, the ability to efficiently analyze research information and compound data using AI can significantly reduce time and costs.
Furthermore, the probability of success up to the clinical trial stage can be increased.
●Optimization of non-clinical studies using AI
・In non-clinical studies, the efficacy and safety of compounds that are candidates for new drugs are verified through animal testing, but by utilizing AI alternative technologies, the number of animal tests required can be reduced.
●Improving the efficiency of selecting investment candidate stocks using AI
・Using alt's clone matching system technologies, it is possible to quickly pick up and list candidate investment issues that meet client’s needs.
The list can also be made from specific products and services in a short period of time.
Reference: Clone matching already announced by alt
CloneM&A：https://alt.ai/news/news-2639/
CloneHR：https://alt.ai/news/news-2631/
Through this collaboration, alt and GNI Group will promote the use of AI in both the drug discovery and investment fields, create new use cases, and contribute to innovation and the creation of new value.
▶For inquiries about LHTM-2/LHTM-OPT/GPT and other large language models solutions
https://alt.ai/aiprojects/gpt/
■ About GNI Group Ltd.
GNI Group is a global pharmaceutical company group based in Japan, the United States, and China that has succeeded in drug discovery and made profits as a pharmaceutical company while demonstrating development capabilities that are recognized around the world. Based on its vision of "bringing new hope to patients," the company strives to develop new drugs and realize limitless growth potential.
https://www.gnipharma.com/english/
■About alt Inc.
Founded in November 2014, alt is a startup that "aims to free people from unproductive labor" by creating P.A.I.®️ (Personal Artificial Intelligence) and AI clones. We also develop and provide various AI products that utilize our variety of foundational AI technologies, including generative AI, a proprietary LLM, and speech recognition technologies. As of April 2024, alt has raised over 10 billion yen.
<Media Inquiries to:>
Misako Nishizawa (Media Relations)
e-mail: press@alt.ai
<Alliance Inquiries to:>
We provide AI solutions and support regardless of genre, including IT, finance, construction, logistics, media, manufacturing, retail, and service industries.
Please feel free to contact us.
Junki Komura (AI Solutions Business Department)
e-mail: ai_solutions@alt.ai